Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia — 301

High Risk Acute Myeloid Leukemia Clinical Trial

Official title:
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML

Status Completed

Clinical Trial Summary

To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01696084
Study type	Interventional
Source	Jazz Pharmaceuticals
Contact
Status	Completed
Phase	Phase 3
Start date	December 13, 2012
Completion date	December 31, 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05066958` - Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT	Phase 1/Phase 2
Recruiting	`NCT05237258` - Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia	N/A
Recruiting	`NCT06394011` - Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients	Phase 2
Active, not recruiting	`NCT02861417` - Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant	Phase 2
Recruiting	`NCT03384212` - CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML	Phase 3
Recruiting	`NCT03384225` - CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML	Phase 3